Validated LC–MS–MS Method for Quantitative Determination of Batifiban in Human Plasma and Its Application to a Pharmacokinetic Study

[1]  Weiyong Li,et al.  Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects , 2009, Journal of Huazhong University of Science and Technology [Medical Sciences].

[2]  L. Newby,et al.  Present and evolving role of eptifibatide in the treatment of acute coronary syndromes , 2007, Expert review of cardiovascular therapy.

[3]  P. Taylor.  Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. , 2005 .

[4]  J. Gibbins.  Platelet adhesion signalling and the regulation of thrombus formation , 2004, Journal of Cell Science.

[5]  C. Bode,et al.  Abciximab, Eptifibatide, and Tirofiban Exhibit Dose-dependent Potencies to Dissolve Platelet Aggregates , 2003, Journal of cardiovascular pharmacology.

[6]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[7]  C. Huck,et al.  Recent developments in polymer-based sorbents for solid-phase extraction. , 2000, Journal of chromatography. A.

[8]  David P Miller,et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.

[9]  J. Tcheng,et al.  Glycoprotein IIb/IIIa integrin blockade. , 1998, Circulation.

[10]  R. Califf,et al.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. , 1995, The American journal of cardiology.

[11]  H. Karnes,et al.  Precision, Accuracy, and Data Acceptance Criteria in Biopharmaceutical Analysis , 1993, Pharmaceutical Research.

[12]  I. Charo,et al.  Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. , 1993, The Journal of biological chemistry.

[13]  R. Seitz,et al.  Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease. , 2008, Current vascular pharmacology.

[14]  S. Mousa,et al.  Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. , 1994, Circulation.